Chronic hepatitis C treated with telaprevir-based triple therapy following interferon combination chemotherapy for non-Hodgkin lymphoma: A case report

Abstract

Three years ago, a man in his 50s, diagnosed as having chronic hepatitis C, received peginterferon-ribavirin combination therapy, which was unsuccessful He was re-examined because of weight loss, which revealed generalized lymphadenopathy and splenomegaly. High sIL-2R level and a biopsy of lymph nodes revealed a diagnosis of low grade B-cell lymphoma (follicular lymphoma). Interferon (IFN) α combined with rituximab (R)-alone and R-combined chemotherapies were administered with marked efficacy. After maintenance therapy with R, telaprevir-based triple therapy was administered. Sustained virological response was achieved; there was no reccurence. An association between hepatitis C virus and B-cell lymphoma has been reported, but no policy for the combination of immunochemotherapy with anti-viral therapy has been established IFN was combined with the initial chemotherapy to suppress liver dysfunction. Triple therapy was performed instead of maintenance therapy. These results suggest that this is an effective treatment considering chronic hepatitis.